Displaying 361 - 380 of 1090
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published Sort ascending
MHRA-101521-PIP01-24-M01 (update)
  • Derivative of 6-(piperidine-1-carbonyl)pyridin-3-ol
  • Treatment of glomerulonephritis and nephrotic syndrome
  • Uro-Nephrology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101189-PIP01-23-M01 (update)
  • Zasocitinib
  • Treatment of psoriasis
  • Dermatology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102037-PIP01-25
  • Coramitug
  • Treatment of transthyretin amyloidosis
  • Cardiovascular Diseases
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100258-PIP01-21-M03 (update)
  • Clesrovimab
  • Prevention of lower respiratory tract infection caused by respiratory syncytial virus
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100046-PIP01-21-M06 (update)
  • cenobamate
  • Treatment of epilepsy
  • Ontozry
  • Ontozry
  • Neurology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102228-PIP01-25
  • Opevesostat tosilate
  • Treatment of Ovarian cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102203-PIP01-25
  • Opevesostat tosilate
  • Treatment of breast cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102191-PIP01-25
  • Opevesostat tosilate
  • Treatment of endometrial cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102041-PIP01-25
  • Daraxonrasib
  • Treatment of pancreatic cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101643-PIP01-24
  • Trivalent mRNA vaccine encoding for NoV VP1 (mRNA-1403)
  • Prevention of acute norovirus gastroenteritis.
  • Vaccines
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-102029-PIP01-25
  • Encaleret
  • Treatment of hypoparathyroidism
  • Endocrinology-Gynaecology-Fertility-metabolism
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100901-PIP01-23-M03 (update)
  • CABOTEGRAVIR
  • Treatment of human immunodeficiency virus (HIV-1) infection
  • Vocabria
  • Vocabria
  • Vocabria
  • Vocabria / Cabenuva
  • Vocabria
  • Vocabria
  • Vocabria
  • Vocabria
  • Vocabria
  • Vocabria / Cabenuva
  • Vocabria / Cabenuva
  • Vocabria
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100594-PIP02-22
  • Azetukalner
  • Treatment of primary generalised tonic-clonic seizures
  • Treatment of epilepsy syndromes
  • Neurology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-102141-PIP01-25
  • Nanvuranlat
  • Treatment of biliary tract cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102060-PIP01-25
  • baxdrostat
  • Treatment of primary aldosteronism
  • Not available at present
  • Cardiovascular Diseases
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101993-PIP01-25
  • avenciguat
  • Treatment of systemic sclerosis
  • Immunology -Rheumatology-Transplantation
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101244-PIP01-23-M01 (update)
  • UPADACITINIB
  • Treatment of vitiligo
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Rinvoq
  • Dermatology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101212-PIP01-23-M02 (update)
  • ENMETAZOBACTAM
  • CEFEPIME DIHYDROCHLORIDE MONOHYDRATE
  • Treatment of infections caused by gram-negative organisms
  • EXBLIFEP
  • EXBLIFEP
  • EXBLIFEP
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102004-PIP01-25
  • olezarsen sodium
  • Treatment of familial chylomicronaemia syndrome
  • Tryngolza
  • Tryngolza
  • Cardiovascular Diseases
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101172-PIP01-23-M01 (update)
  • Disitamab vedotin
  • Treatment of solid tumours, including central nervous system malignancies
  • Aidixi
  • Aidixi
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No